BCBS Utah Wegovy Prior Authorization: How It Actually Works in 2026

Published by Weight Loss Provider Guide · Published August 15, 2026 · Last verified: August 15, 2026

BCBS Utah Wegovy prior authorization runs through Regence BlueCross BlueShield of Utah. Regence is Utah's local Blue plan. Most contracts that use Regence medication policy dru787 require prior approval for Wegovy, but your own benefit contract decides whether the drug can be covered.

For weight management, there are two gates, not one.

Gate 1 is your plan. Does it include medications for obesity or weight reduction? Regence's rulebook says the weight route cannot be approved when the contract excludes that benefit, no matter how well you meet the medical rules.

Gate 2 is your health. For adults, the usual weight route starts at a BMI of 30 or more, or 27 or more with at least one weight-related condition.

Almost every quick answer skips straight to Gate 2. That is why so many people get blindsided.

Now the part that can change the outcome. Regence's current policy has four clinical paths. The weight-benefit sentence appears in the weight and sleep-apnea paths. It does not appear in the heart-risk or MASH liver-disease paths. That does not guarantee payment or erase the rest of your contract. It does mean that a medically accurate Wegovy request for an FDA-approved heart or liver use should be reviewed under that exact use, not pushed through the weight-loss door by mistake.

We will show you all four paths, who they fit, the current Utah decision clock, what changes on January 1, 2027, and exactly what to do next.

This page explains coverage rules. It is not medical or legal advice. Your prescriber decides what treatment is medically right, and your plan documents decide what is covered.

What we actually verified

We did not summarize other articles. We opened the documents.

Verified on August 15, 2026:

• Regence's live GLP-1 policy — Medication Policy Manual dru787, version dru787.6, approved July 9, 2026, effective August 15, 2026. Read start to finish.
• Regence's latest published Utah membership figure — more than 702,000 members at the end of 2023; retained as a dated figure, not presented as a 2026 count.
• Premera's weight-management policy — policy 5.01.621, effective July 1, 2026. Read side by side with Regence's policy.
• A published Regence Utah Silver 6500 individual policy — form UU0126PMEDGSIE, effective December 1, 2026, including its exclusion, drug cost-sharing, deductible, and coupon language.
• Six published Regence Utah individual policy documents — two effective December 1, 2025, and four effective December 1, 2026. Every document in this sample contains a weight-reduction exclusion that includes medication.
• Current Utah Code 31A-22-650 and the enacted 2026 Senate Bill 319. The new deadlines and added rights in SB 319 do not take effect until January 1, 2027.
• Utah Administrative Code R590-261 and R590-203 — the state's independent-review rules.
• PEHP's public weight-management page, the 2026-27 State of Utah Benefits Guide, and Utah HCR 8.
• Utah Medicaid's current prior-authorization directory.
• CMS's Medicare GLP-1 Bridge page.
• FEP Blue's 2026 pharmacy materials and current Wegovy prior-approval result.
• Novo Nordisk's current Wegovy price guide and savings-offer terms.
• Ro's current GLP-1 coverage checker, membership pricing, and insurance-service descriptions.
• Current FDA labeling for Wegovy injection, tablets, and Wegovy HD — including the product-specific adult cardiovascular, MASH, weight-management, and pediatric dose limits.

What we could not verify for you personally:

• Whether your exact plan covers Wegovy.
• Your copay, deductible, coinsurance, tier, or approved pharmacy.
• Whether your employer's contract includes the weight-loss medication benefit.
• Whether a denial is medical, contractual, formulary-based, or caused by the wrong product being billed.

Your own certificate, drug list, denial letter, and member record answer those questions. We will show you how to get the answer in writing.

How we make money: Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. Some providers may pay us when a reader enrolls. The manufacturer savings card, NovoCare direct pricing, Utah appeal route, and insurer phone scripts earn us nothing, and they come first because they are often the better move. No insurer, drug maker, or telehealth company paid for or reviewed this page.

What are the four clinical paths in Regence's GLP-1 policy?

This is the table we built by reading each criteria section in dru787.6 and checking one thing: does this path repeat the requirement that the plan include weight-loss medication coverage?

There is a real policy-label mismatch inside those rows. Regence groups standard Wegovy and Wegovy HD together in the heart and MASH criteria. The current FDA label does not make the 7.2 mg HD dose interchangeable across those uses:

• Cardiovascular risk reduction: FDA-labeled maintenance is Wegovy injection 1.7 or 2.4 mg weekly, or Wegovy tablet 25 mg daily.
• MASH: the recommended FDA-labeled maintenance dose is Wegovy injection 2.4 mg weekly; the label allows a decrease to 1.7 mg if 2.4 mg is not tolerated. The tablet and 7.2 mg HD dose are not established for MASH.
• Adult weight reduction: 7.2 mg HD may be used after at least four weeks at 2.4 mg when more weight reduction is clinically needed.

So “Wegovy/Wegovy HD” in an insurer PDF is not permission to use every form or dose for every diagnosis. The prescription still has to match the current FDA label and the patient's care.

Read the middle two rows again. The heart and liver sections do not repeat the weight-benefit condition. The sleep-apnea section does.

But do not turn that into a promise the policy does not make. The first page says the member contract controls whenever contract language and the medical policy conflict. The right takeaway is this:

• A written weight-loss exclusion closes the weight path.
• It also closes the policy's Zepbound sleep-apnea path because that section repeats the weight-benefit rule.
• If you truly have the heart or MASH condition, the request should name that exact diagnosis and FDA-approved use.
• Your contract, formulary, exact product, and other plan rules still decide whether the claim is paid.

Regence explains its sleep-apnea rule itself: Zepbound improves obstructive sleep apnea mainly through weight loss, so the weight-benefit condition stays attached. The heart and liver sections are written differently.

That difference is not a paperwork trick. It is a reason to make sure the request is filed under the condition your doctor is actually treating.

Who actually covers you when your card says Blue Cross in Utah?

Utah's local Blue Cross Blue Shield plan is Regence BlueCross BlueShield of Utah, part of Cambia Health Solutions. In its latest public Utah membership figure, Regence said it ended 2023 serving more than 702,000 people, including self-funded and BlueCard members. Regence says Prime Therapeutics is its pharmacy benefit manager for group, individual, and Medicare members, although a self-funded employer may use a different pharmacy arrangement. But a blue card used in Utah can also belong to FEP Blue, a Medicare plan, or another state's Blue company. Each one can use a different Wegovy rulebook.

Before you read one more word about BMI, figure out which card you are holding. This can matter more than your weight.

The Utah blue-card register

A federal employee and a Utah state employee can live on the same street, carry health coverage tied to public work, and get opposite answers. Same state. Same drug. Different contract.

How to tell in ten seconds

Flip the card over. Look for:

• The Regence name — that is Utah's local Blue plan.
• FEP or Service Benefit Plan — use FEP Blue's rules and pharmacy channel.
• A PEHP logo — you are not on a Blue plan.
• Another state's Blue company — call the number on that card, not Regence's general line.
• A Medicare label or Part D plan name — read the Medicare section below.

Still cannot tell? Ask the number on the back:

“Who is the legal insurer? Who handles the pharmacy benefit? Is this plan fully insured or self-funded? Which document controls a Wegovy request?”

That self-funded question matters. Utah insurance mandates generally govern insurance contracts. A self-funded employer plan is usually governed by federal benefit law and its own plan document instead.

Find your Utah rulebook

Use this no-data decision tree before you send anything. No member ID. No email. Nothing saved.

Your next move: use the first row that matches your card, then follow that plan section before you spend time on BMI paperwork.

How does BCBS Utah Wegovy prior authorization work?

Most Regence contracts using dru787.6 require preauthorization for Wegovy. For the weight route, approval means clearing two separate hurdles: the contract must include weight-loss medication coverage, and the clinical record must meet the policy. The contract hurdle can stop the weight request before BMI is even considered.

Here is the line that decides many weight-management cases. Regence says coverage for obesity or overweight cannot be approved when the benefit contract excludes that treatment, regardless of the clinical criteria met.

Sit with that for a second.

You could have a BMI of 42. You could have high blood pressure, sleep apnea, and a doctor's note three pages long. If the written contract excludes the category, none of that opens the weight route. The policy says so in plain English.

This is not just a clinical-policy problem. It is a plan-design problem. In employer coverage, the plan sponsor and the contract it chose decide which benefit categories exist. Regence then administers those rules.

The one phone call that answers Gate 1

Call the number on your card and ask this, word for word:

“Does my plan include coverage for medications used to treat obesity or weight reduction? I am not asking only whether Wegovy appears in the drug-search tool. I am asking whether this benefit category exists in my contract.”

Then ask:

“If the category is excluded, was that exclusion chosen by the plan sponsor, and is any rider, exception, or different plan option available?”

Ask for the answer and the controlling policy section in writing through the member portal.

If the plan is self-funded, your HR or benefits team may be able to answer the plan-design part faster. Regence can still process claims, but the employer plan document may be the controlling contract.

One call can save you weeks of paperwork that was never going to open the weight route.

What BMI and medical rules does Regence use for Wegovy?

For the adult weight route, Regence requires a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. A new-start request also needs an attestation that the medicine will be used with lifestyle changes. The example list is broader than many summaries: it includes prediabetes and insulin resistance.

The adult weight route, in full

Adults 18 and older need one of these:

• BMI of 30 or higher, or
• BMI of 27 or higher plus at least one weight-related condition.

Regence's example conditions are:

• High blood pressure.
• High cholesterol or triglycerides.
• Type 2 diabetes.
• Prediabetes.
• Insulin resistance.
• Obstructive sleep apnea.
• Cardiovascular disease.
• Symptomatic arthritis in the lower legs, such as painful hip, knee, ankle, or foot arthritis.

The policy puts “for example” before that list. That makes it an example list, not a closed list. It does not mean every condition will be accepted. It means the reviewer is not limited to only those eight words.

If you are at BMI 28 with documented prediabetes, that detail matters. It does not create the benefit, but it can satisfy the listed medical route when the benefit exists and the rest of the request is complete.

One rule applies to every new-start path: the prescriber must attest that the medication will be used with lifestyle modification, such as diet or calorie changes, exercise, a weight-management program, nutrition counseling, or behavioral therapy.

Kids and teens, ages 12 to 17

Regence's policy says:

• Wegovy/Wegovy HD: BMI at or above the 95th percentile for age and sex.
• Liraglutide, including generic or Saxenda: a separate Cole-criteria BMI threshold plus body weight over 60 kg.
• Zepbound: not listed as coverable for pediatric obesity in this policy.

Here is a policy-label mismatch parents and prescribers should not miss: the insurer writes “Wegovy/Wegovy HD” together, but current FDA labeling does not establish the 7.2 mg Wegovy HD dose for pediatric patients. Wegovy tablets are also for adults. The FDA-supported adolescent weight-management maintenance doses are the 1.7 mg or 2.4 mg injection. An insurer's slash mark is not FDA approval for a higher pediatric dose.

How much the policy allows at one time

A quantity limit is not a formulary promise. The plan still must cover the exact product. That matters now because Regence's policy lists Wegovy HD, while Novo Nordisk's own coverage checker says no insurance coverage is currently available for the 7.2 mg product as of August 15, 2026.

What dru787.6 calls investigational or not medically necessary

Under this specific policy, Regence says:

• Using two obesity or weight-loss medications together is investigational. That includes pairing a listed GLP-1 with Contrave or Qsymia.
• These products are not medically necessary for type 2 diabetes without obesity or overweight under this non-diabetic-indications policy.
• Use for type 1 diabetes or diabetic ketoacidosis is investigational.
• The sleep-apnea route does not cover central or mixed sleep apnea, Cheyne-Stokes breathing, or obstructive sleep apnea caused by major craniofacial abnormalities.

Do not turn “investigational under this policy” into “never covered for any reason anywhere.” It tells you how dru787.6 treats the request. Your exact drug, diagnosis, FDA label, and other policies still matter.

Print-friendly Regence prescriber checklist

Hand this to the office instead of hoping the right facts make it into the request.

• Exact product and form: Wegovy pen, Wegovy tablet, or Wegovy HD — not just “semaglutide.”
• Exact clinical path: weight, cardiovascular risk reduction, MASH, or another policy route.
• Current height, weight, BMI, and measurement date.
• For BMI 27-29.9, the documented weight-related condition.
• For the heart path, the prior MI, stroke, or symptomatic PAD proof, plus current optimized cardiovascular medication plan.
• For MASH, specialist involvement and F2/F3 proof by biopsy, VCTE, ELF, or MRE.
• Lifestyle-modification attestation for a new start.
• Confirmation of the weight-loss medication benefit when using the weight or Zepbound OSA path.
• Current medication list to avoid a dual-weight-loss-drug conflict.
• If continuing treatment after a plan change, proof that another health plan covered the medicine.
• CoverMyMeds submission key, date, and reference number.

Print or copy this checklist before the office sends the request. (No email.)

“Prior authorization required” does not mean “covered”

These are four different problems with four different fixes: prior authorization required, not on the drug list, benefit excluded, and the wrong product or benefit being billed. A message saying Wegovy needs prior authorization tells you the plan wants paperwork. It does not prove that your contract covers the request.

This is where people lose weeks.

A drug-search tool and a benefit contract are two different systems. The search tool can show a product's status while the contract excludes the whole category. A denial can also name a pharmacy-benefit problem even though someone first tried to bill the medical benefit. Regence's policy says these self-administered products are coverable only under the pharmacy benefit.

The honest answer is not “appeal everything.” It is: find out which kind of no you received.

The status decoder

The script for a contradiction

“My portal says Wegovy is covered with prior authorization. My letter says it is not covered under my pharmacy benefit. Please tell me which document controls and send me the exact section — the clinical criteria, drug-list rule, product rule, or benefit exclusion.”

Write down the date, the representative's name or ID, and the reference number. If you appeal, that record matters.

What if my plan excludes weight-loss drugs?

If the written contract excludes weight-loss medication, no BMI number and no medical-necessity appeal opens Regence's weight route. But dru787.6 does not repeat that benefit sentence in its heart-risk and MASH sections. If you truly have one of those conditions, the request should use the medically correct FDA-approved indication. That is a different route, not a guarantee.

This is the most useful distinction on this page. Read it carefully.

How we found it

We opened Regence's policy and checked all four criteria sections for the same contract sentence.

Two sections have it. Two do not.

The obesity/overweight section has it. The Zepbound sleep-apnea section has it. The Wegovy cardiovascular and MASH sections do not.

That is not permission to change a diagnosis. It is a reason not to code a real heart or liver treatment as simple weight management.

The heart path

This route is for adults with established cardiovascular disease who meet the policy. Regence requires:

• At least one of these: a past heart attack, a past stroke, or symptomatic peripheral artery disease.
• A BMI of 27 or higher.
• An attestation that optimized cardiovascular treatment, such as blood-pressure and cholesterol medicine, will continue with Wegovy.

“Symptomatic peripheral artery disease” means poor blood flow with accepted proof. Regence lists leg symptoms with a resting ankle-brachial index below 0.85, a past peripheral revascularization procedure, or amputation from atherosclerotic disease.

Regence does not add a 45-year minimum to this section. But the FDA cardiovascular indication is for adults. The absence of a 45+ insurer rule is not pediatric approval.

The MASH liver path

For noncirrhotic metabolic dysfunction-associated steatohepatitis, Regence requires:

• A diagnosis by or in consultation with a gastroenterologist or hepatologist.
• Stage F2 or F3 fibrosis confirmed by liver biopsy, vibration-controlled transient elastography, an enhanced liver fibrosis score, or magnetic resonance elastography.

In June 2026, Regence removed the old MASH requirement to first fail weight-loss goals with diet and exercise. It also updated the accepted fibrosis tests. If an office is using an older checklist, the rules moved.

The FDA MASH indication is for adults with noncirrhotic MASH and F2-F3 fibrosis. Again, insurer wording does not expand the FDA label to children.

The honest limit on this

These are real medical conditions, not paperwork tricks. Your doctor decides what is being treated based on your health. Changing a diagnosis to get payment would be fraud and could put the patient and prescriber at risk.

What we are saying is narrower: if you already have established cardiovascular disease or confirmed MASH, and the request was filed only as weight loss, ask your prescriber whether the exact approved indication should be used.

Utah's individual market: where the distinction matters most

We reviewed six published Regence Utah individual policy documents. Every document in this sample contains a general exclusion for obesity or weight-reduction treatment that includes medication.

What that means in practice: if your own individual certificate contains that exclusion, the weight route is closed. The heart or MASH route may still be reviewed under the exact condition, but it is not automatically open. The contract, formulary, FDA indication, and policy still control.

This is a six-document sample, not a ruling on every Regence certificate. Employer, federal, Medicare, and other plans are separate. Your own document wins.

The honest part

If your contract excludes weight-loss drugs, nobody can create that benefit for you — including us and including the companies that pay us.

Telehealth platforms can prescribe, check benefits, and submit paperwork. They cannot rewrite an exclusion. A medical appeal cannot force a plan to add a benefit it did not promise. If a company says it can make a written exclusion disappear, walk away.

Stepping outside insurance removes the insurer's PA and insurer renewal rules. It does not remove the need for a real prescription or clinical follow-up. It also does not freeze the cash price forever; manufacturer programs can change or end.

For someone whose plan covers Wegovy, paying cash is usually a bad trade. Go fight for the benefit you already have.

For someone holding a clear exclusion, cash may be the only immediate path on the table.

Not sure which one you are? → Use the Utah rulebook router before you decide anything.

Do I have to try diet and exercise for three months first?

Not under current Regence dru787.6. Regence requires a forward-looking attestation that the medicine will be used with lifestyle changes. It does not require a documented three-month waiting period. Premera, the Blue plan for Washington and Alaska, does require a documented three-month trial.

Let's kill this myth properly, because it costs Utah readers real time.

We compared the policies line by line:

Now take one example: a Utah adult at BMI 28 with documented prediabetes and no three-month program record.

Under Regence: that person would clear the listed BMI-and-condition piece and would not face a three-month look-back, if the weight-drug benefit exists and the rest of the request is complete.

Under Premera: the same record would miss two listed requirements — prediabetes is not on the closed comorbidity list, and the three-month record is missing.

Same drug. Same month. Blue Cross both times. Different answers.

A good record still helps. Complete chart notes reduce missing-information delays. They do not create coverage and do not guarantee a deadline outcome.

How is a Regence Wegovy request submitted, and how long can it take?

Regence tells providers to submit pharmacy prior authorizations electronically through CoverMyMeds. As of August 15, 2026, Utah's current statute still points pre-service claims to the federal claims rule: generally 15 calendar days for a non-urgent decision, with a possible extension, and no later than 72 hours for an urgent claim. Utah's new seven-day rule starts January 1, 2027 — not before.

That date matters. The enacted law changed during the legislative process. The final version is not the five-business-day rule described in the draft.

The clock that applies now

Under the current Utah statute and the federal pre-service rule it incorporates:

Your contract can promise a faster answer. A drug-list exception may also use a different federal clock. Ask which process and deadline the plan is applying to your exact request.

What Utah SB 319 changes on January 1, 2027

The final law does not say the first page must show the price and your cost share. It says billing codes.

The 12-month question

Starting January 1, 2027, the law says authorization for a drug used to treat a chronic or long-term condition generally cannot be shorter than 12 months. It defines that type of condition as lasting at least three months and needing ongoing medical attention or limiting daily activities.

The law also allows shorter or changed authorization in listed situations, including an experimental drug, lack of effectiveness, a more effective option, an equally effective lower-cost option, or loss of formulary coverage.

We are not saying obesity automatically wins that legal question. If a plan offers a short approval after January 1, ask which section and exception it is using.

The self-funded catch

State insurance rules generally do not control a private employer's self-funded benefit plan. Those plans usually follow federal law and the written plan document. A Regence logo does not answer this.

Ask HR:

“Is this plan fully insured or self-funded, and which prior-authorization deadline applies?”

What to do after submission

Get four things from the office:

1. Submission date.
2. CoverMyMeds key or reference number.
3. Exact product and dose requested.
4. Which clinical path and diagnosis were used.

Then ask the plan:

“Was the request received? Is anything missing? Is this a standard PA, a formulary exception, or another process? What is the deadline under this plan?”

Silence can mean missing information, a routing problem, or a delayed review. Do not guess which one. For the broader claims map, see our GLP-1 prior authorization guide.

What happens at renewal — do I have to lose 5%?

For the adult weight route, Regence asks for either a 5% reduction from starting weight or proof that the dose is still being increased. The word “or” matters. Regence also rechecks the benefit contract at least yearly, so coverage can end at a plan-year change even when the medicine is working.

Almost every short answer says, “You must lose 5%.” The current policy has another route.

• Adults on the weight route: at least 5% loss from pretreatment weight or the dose is still being titrated upward.
• Ages 12-17 on an allowed pediatric product: any reduction from starting BMI or the dose is still being titrated upward.
• Heart path: continued use of optimized cardiovascular treatment with the requested medicine.
• MASH path: clinical benefit, such as stable or improved fibrosis stage.
• Zepbound OSA path: improvement in sleep quality, daytime function, or AHI.

The renewal nobody warns you about

Regence reviews the benefit contract at least annually.

So this can happen: you lose 14% of your body weight, do everything right, and the next claim still stops. Not because of your result. Because the employer changed the plan and removed the benefit.

If open enrollment is coming, ask HR:

“Is the obesity and weight-loss medication benefit staying in the plan next year?”

Ask before the plan year flips, not after the pharmacy rejects the fill.

I have been paying cash for a GLP-1. Does that history count?

Probably not the way you hope. Regence has a continuation-of-therapy shortcut, but it requires documentation that another health plan covered the medicine. The policy says samples, coupons, promotions, cash payment, and other ways of getting medication outside an established health-plan benefit do not necessarily establish medical necessity.

This one stings.

If you were on the medicine before joining the current plan and another plan covered it, Regence can review the continuation criteria instead of making you prove every new-start item again.

The words doing the damage are another health plan.

So eight months of NovoCare self-pay, a manufacturer offer, or a compounded-semaglutide subscription may not buy the shortcut. A compounded product is also not the same FDA-approved Wegovy product.

What to do instead: do not force cash history into a rule it does not fit. File a complete new-start request if that is the route the plan requires.

If you are changing jobs or plans, save proof of coverage, prior approvals, paid claims, starting weight, current dose, and response before the old portal closes. That is much harder to recover after coverage ends.

What if I am on PEHP, Utah Medicaid, Medicare, or FEP Blue?

These are four different systems. Regence writes the rules for none of them. PEHP now has a narrow State of Utah pilot, Utah Medicaid's live form changed after the old pilot window, Medicare has a separate $50 Bridge, and FEP Blue uses federal-plan rules and CVS Caremark.

PEHP — Utah public employees

PEHP's general weight-management page still says GLP-1 coverage under ordinary health benefits does not extend to weight loss. It points members to discount vendors for services that are not covered benefits.

But that is no longer the whole answer for every PEHP member.

The 2026-27 State of Utah Benefits Guide says that beginning July 1, 2026, eligible State of Utah members may choose GLP-1 medication as part of the Weight Management Program instead of bariatric surgery. That is a special pilot, not a broad benefit for every school district, city, county, or PEHP group.

Utah HCR 8 directed these pilot terms:

• Reimbursement-based administration.
• 50% member cost sharing.
• Monthly PEHP allowed pharmacy expense capped at $300 per member.
• Maximum 24 months in the medication path.
• Health coaching and other participation rules.
• A one-time choice between the GLP-1 path and bariatric surgery, except a member who stops the GLP-1 within six months may enter the surgery path.
• Operation inside the bariatric pilot's adjusted annual budget of $1,050,000.
• A report to lawmakers before December 1, 2026, and annually through 2028.

The resolution does not explain clearly whether the $300 cap is the total allowed drug amount before the 50% member share or the amount PEHP itself pays. So a single capacity number would be fake precision.

That is our arithmetic, not a promised enrollment count. Either way, this is a narrow, capped pilot — not open-ended coverage. Our state-employee GLP-1 coverage research tracks how public plans handle programs like this.

If your card says PEHP, ask:

“Am I an eligible State of Utah Weight Management Program member, or am I in a different PEHP employer group? What is the reimbursement process, approved drug list, and member cap?”

Utah Medicaid

The old Utah Medicaid fee-for-service GLP-1 weight-loss pilot authorization window ended June 30, 2026. Stopping there would now be misleading.

The live Utah DHHS prior-authorization directory lists a newer form titled “GLP-1 Medications for Weight-related Comorbidities,” revised June 19, 2026. That means the right current answer is not a blanket yes or no.

Ask two questions:

1. Am I in Utah Medicaid fee-for-service or a managed-care plan?
2. Which current GLP-1 form and indication apply to me?

A managed-care plan can have its own drug list and PA channel. A cardiovascular or MASH request also needs to use the exact current indication, not an old weight-loss-pilot summary.

Medicare

Standard Part D still cannot pay for a drug when it is used only for weight loss. But two routes now exist:

1. Part D for another FDA-approved indication. Wegovy may be covered under the plan's normal prior-approval rules for a covered cardiovascular or MASH use. Other GLP-1 products can have their own covered indications.
2. The Medicare GLP-1 Bridge. This separate CMS demonstration runs from July 1, 2026, through December 31, 2027. Eligible Part D beneficiaries pay $50 for a 30-day supply. It operates outside the Part D payment flow, so the $50 does not count toward the Part D deductible or TrOOP.

The Bridge currently lists Foundayo tablets, Wegovy injection or tablets, and Zepbound KwikPen. The exact product matters; it does not cover every Zepbound form.

The current Bridge screen says you must be 18 or older, have Part D, and meet one of these starting points:

• BMI 35 or higher; or
• BMI 30 or higher with heart failure with preserved ejection fraction, uncontrolled high blood pressure, or stage 3a-or-higher chronic kidney disease; or
• BMI 27 or higher with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease.

You are not eligible through the Bridge if Part D already covers your GLP-1. The Bridge also sends people with type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease back to their Part D plan because the drug may be covered for those conditions.

→ Check Medicare GLP-1 Bridge eligibility at Medicare.gov

FEP Blue — federal employees

Federal employees start in a better position than many employer-plan members because OPM requires FEHB carriers to cover at least one GLP-1 anti-obesity drug. An employer office cannot individually remove the entire class from the federal plan.

That does not mean every FEHB option must cover Wegovy at the same tier or without conditions. FEP Blue's current 2026 drug tool shows Wegovy needs prior approval.

Two practical rules:

1. Use FEP Blue's current pharmacy materials and CVS Caremark channel, not Regence's standard commercial route.
2. Check your exact FEP option, product, dose, tier, and current prior-approval policy.

Novo Nordisk's current savings terms say FEHB coverage is not treated as a government program for the commercial savings offer. Eligibility still depends on all other terms.

It got approved. Why is Wegovy still expensive?

Approval decides whether the plan will pay under its rules. It does not decide whether your share is affordable. Novo Nordisk's commercial savings offer can bring an eligible covered prescription down to as little as $25, but the current maximum savings is $100 per month. It reaches $25 only when the plan-approved amount you owe is $125 or less.

This is where the next disappointment lands.

The $25 math, done honestly

The last row is an illustration, not a quote for your plan.

We pulled Regence's published Silver 6500 individual policy effective December 1, 2026. It shows:

• Generic: $10 copay.
• Preferred brand: 20% coinsurance.
• Brand: 40% coinsurance.
• Specialty: 50% coinsurance.
• Individual deductible: $6,500.

Novo's posted Wegovy list price is $1,349.02. Forty percent is $539.61. But your actual coinsurance is usually based on the plan's allowed amount and the assigned tier — not automatically the public list price.

And here is the important contradiction: that same Silver 6500 document excludes weight-reduction medication. So this is not proof that it pays for Wegovy weight loss. It is a real example of how expensive a covered brand claim could be if Wegovy were payable under another indication or benefit.

“Approved” and “affordable” are two different events. Find the tier and allowed amount before you celebrate.

The coupon trap in the fine print

The Silver 6500 policy says a manufacturer coupon or discount reduction may not count toward the deductible or out-of-pocket maximum.

Novo's current savings terms go further. If your plan uses a copay accumulator or maximizer — a program that does not credit the manufacturer's help or changes your cost share because assistance exists — Novo says you are not eligible to use the offer and must stop if you learn you are in one.

So do not rely on the card until you ask both sides:

“Does this plan use a copay accumulator, maximizer, or alternate-funding program for Wegovy? Will the manufacturer's amount count? Do Novo's current terms allow me to use the offer?”

A self-pay NovoCare fill is processed outside insurance. It will not count toward your deductible or out-of-pocket maximum.

Questions to ask before the first fill

• What exact Wegovy product and NDC was approved?
• Is it a flat copay or a percentage?
• What tier is it on?
• What is the plan's allowed amount at this pharmacy?
• What do I pay before and after the deductible?
• Does the plan use an accumulator, maximizer, or alternate-funding program?
• Does a different network pharmacy or mail service change the cost?
• Is the pen covered differently from the tablet?
• Is Wegovy HD covered at all? Novo's checker currently says no insurance coverage is available for 7.2 mg.
• When does the authorization expire?

Medicare, Medicaid, VA, DOD, and TRICARE beneficiaries are not eligible for the commercial copay offer. Novo's current terms say FEHB, exchange coverage, and state-employee insurance are not treated as government programs for this offer, but every other eligibility rule still applies.

Regence denied my Wegovy. What now?

Read what kind of “no” you received before you do anything. A medical-necessity denial can be appealed. For eligible Utah-regulated coverage, an independent reviewer can overturn it, the carrier pays the review cost, and the result binds the carrier and claimant. A true benefit exclusion is different because external review does not expand the contract.

This fork is the difference between a fight worth having and six weeks of wasted paperwork.

The denial decoder

Utah's independent review

For a standard eligible request under Utah's rule:

• You generally have 180 calendar days after the final adverse benefit determination to request independent review.
• The carrier pays the independent-review organization's cost.
• The decision binds the carrier and claimant, except where another legal remedy remains.
• A standard decision is due within 45 calendar days after the request is received.
• An expedited review can be decided within 72 hours when the medical standard is met.
• If you mistakenly send the request to the carrier, the carrier must forward it to the commissioner within one business day.

The request still has to be eligible. The service generally must be a covered benefit, the internal review must be exhausted unless an exception applies, and the denial must involve medical or scientific judgment. A true exclusion normally fails the covered-benefit test.

Self-funded employer plans may use a federal or plan-run external-review process instead of Utah's route. Read the final denial letter for the controlling instructions.

→ Open Utah’s independent-review page or download the current request form.

Utah Wegovy appeal checklist

• Final denial letter and every page of the plan's appeal instructions.
• Exact denial reason copied word for word.
• Benefit certificate section showing the requested service is covered, when applicable.
• Current drug-list page and exact product/NDC.
• Regence dru787.6 criteria for the correct clinical path.
• Chart notes with height, weight, BMI, diagnosis, dates, and prior treatment.
• Lifestyle attestation for a new start.
• Heart, MASH, or OSA records if that is the real indication.
• Baseline and current response data for renewal.
• CoverMyMeds key, submission date, plan call references, and names/IDs.
• Internal appeal decision and date received.
• Independent-review deadline written on your calendar.

Copy the denial reason word for word before you build the appeal.

What does Wegovy cost if I stop fighting for insurance?

The current verified cash ladder starts at $149 for the lowest tablet dose through NovoCare. Standard-dose pens are $349 per month, with a limited $199 first-two-fill offer for eligible new users at the two starter pen doses. Wegovy HD is $399. These are manufacturer program prices, not permanent list prices, and Novo can change or cancel them.

Insurance is worth fighting for when the benefit exists and the final cost is good. A written exclusion is different. Once you have confirmed it, the cleanest move may be to compare the real cash paths instead of paying someone to file paperwork that cannot change the contract. See the full Wegovy cost-without-insurance ladder for the longer price comparison.

Option 1: The commercial savings offer — when insurance covers Wegovy

For eligible people with commercial coverage, Novo says the savings offer can reduce a one-month covered prescription by up to $100, to as little as $25.

This is not a cash-price program. It does not create coverage. Accumulator, maximizer, alternate-funding, and government-program rules matter.

Cost to use: $0.
What we earn: $0.

Option 2: NovoCare direct — when you already have a prescription

Current posted self-pay prices:

A month is one box of four pens or one bottle of 30 tablets, as stated in the program terms. A real prescription and clinical care are still required. Self-pay fills do not count toward an insurance deductible or out-of-pocket limit.

→ See current NovoCare Wegovy pricing

Cost to use: the posted medicine price.
What we earn: $0.

Option 3: Telehealth — when you need a prescriber or insurance help

This is where a platform can earn its fee. The useful question is not “Can they prescribe?” It is “What work do they do before and after the prescription?”

Ro's current position:

• The free checker reports benefit results for the Ozempic pen, Wegovy pen, and Zepbound pen. It does not currently check Wegovy tablets, Wegovy HD, Foundayo, or Zepbound KwikPen.
• The checker itself does not prescribe and does not submit a treatment PA.
• If you enroll and receive care through Ro, Ro says its insurance concierge verifies coverage and submits or manages prior-authorization paperwork.
• Ro Body costs $39 for the first month, then $74 per month equivalent when an annual plan is prepaid, or $149 per month on the monthly plan. Medication is separate.
• Ro says insurance PA often takes one to two weeks, but the insurer and missing records can make it longer. Approval is not guaranteed.

The trade-off, stated plainly. If your own clinic will file a complete request and you trust it, stay there. You do not need to buy a membership just to make a PA possible. If you need a prescriber, follow-up care, and someone to manage the insurance paperwork, the membership may earn its cost. If the contract has a clear exclusion, Ro cannot create the missing benefit.

Check Wegovy pen coverage free with Ro — no membership required for the checker

Affiliate disclosure: Ro is an affiliate partner. That does not change the order on this page: the no-cost insurer call, manufacturer offer, direct manufacturer price, and appeal route come first.

Also worth comparing: Sesame, if you prefer to choose a clinician and compare branded-medication visits. Verify the exact drug, total price, insurance service, and state availability before paying.

Why we are not mixing compounded semaglutide into this page

Wegovy is an FDA-approved product. Compounded semaglutide is not Wegovy and is not FDA-approved. FDA does not review a compounded drug for safety, effectiveness, or quality before it is sold. A compound may have a role in a lawful, patient-specific situation, but it is a different decision and a different coverage question.

Putting the two in one “Wegovy price” table would blur a distinction that matters.

Why do two Blue Cross plans in the same region have different rules?

Because Blue Cross Blue Shield companies are independently operated and can write different drug policies. Regence serves Utah and other Northwest markets. Premera serves Washington and Alaska. Their July/August 2026 policies disagree on the three-month trial, which comorbidities count, the first approval period, the renewal test, and whether MASH appears as a Wegovy route.

They share a brand. They do not share one national rulebook.

That is why an article saying “BCBS requires three months of diet and exercise” can be true for Premera and false for Regence on the same day.

When you read any Blue Cross Wegovy answer, ask:

“Which Blue company, policy number, version, and effective date is this describing?”

If the answer is missing, do not use it to plan your request.

And if you move or change jobs, assume nothing carries over. New plan, new contract, new drug list, and often a new PA.

How we researched this

We used official policies, statutes, regulator rules, FDA labeling, and current manufacturer/provider pages first. We recorded version numbers and effective dates. We separated what an organization says from what the document actually proves.

Primary-source log

Provider-stated versus source-verified

Our source order: your own plan document wins. Then the current drug list and insurer criteria. Then your denial letter and appeal instructions. State and federal rules tell you the process. FDA labeling tells you the approved product and use. Manufacturer and provider pages tell you their own current program terms.

What we still cannot verify from public documents: your exact benefit, exact tier, allowed amount, PA history, employer choice, and final eligibility for any savings or pilot program.

Found something out of date? Coverage changes fast. Send the replacement document and effective date. We will correct the page and keep the visible verification date honest.

Who we are: Weight Loss Provider Guide is an independent comparison publisher. No insurer, drug manufacturer, or telehealth company reviewed or approved this page.

Frequently asked questions

Is BCBS Utah the same as Regence?
Regence BlueCross BlueShield of Utah is Utah's local Blue plan. A Blue card used in Utah can still be FEP Blue, another state's Blue plan, or a Medicare plan, so read the name and pharmacy administrator on the card.

Does Regence cover Wegovy?
It depends on the contract, exact product, indication, and clinical criteria. For weight management, the plan must include the benefit. Every individual policy in our six-document sample excludes weight-reduction medication, but your own certificate controls.

What BMI does Regence require for the weight route?
Adults need BMI 30+, or BMI 27+ with at least one weight-related condition. The example list includes prediabetes and insulin resistance.

Does Regence require prior authorization for Wegovy?
Most contracts using dru787.6 require it. The current policy version became effective August 15, 2026. PA required does not prove the benefit exists.

Do I have to try diet and exercise for three months first?
Not under current Regence dru787.6. It requires a lifestyle-modification attestation, not a three-month look-back. The documented three-month rule belongs to Premera's current policy.

How long can a Regence decision take right now?
For a standard non-urgent pre-service request governed by current Utah and federal claims rules, generally 15 calendar days after receipt, with a possible extension. Urgent requests are generally due within 72 hours. Utah's seven-calendar-day rule starts January 1, 2027.

Where is the PA submitted?
Regence directs providers to CoverMyMeds for pharmacy prior authorization. FEP Blue uses its federal-plan pharmacy route through CVS Caremark.

Can PA override a weight-loss exclusion?
Not for Regence's weight route. The policy says the route cannot be approved when the contract excludes the benefit. The heart and MASH sections do not repeat that sentence, but those routes still require the real diagnosis, exact FDA-approved indication, formulary coverage, and all other contract rules.

Can I appeal a Wegovy denial in Utah?
Yes when the denial and plan are eligible. After the internal appeal, a claimant generally has 180 days to ask for Utah independent review. The carrier pays the review cost, and the decision is binding. A true benefit exclusion usually is not an eligible medical-necessity dispute.

What does “not covered under your pharmacy benefit” mean?
It can mean an exclusion, nonformulary product, wrong NDC, wrong benefit, or exact-form mismatch. Ask for the controlling document and section before choosing an appeal.

Does PEHP cover Wegovy for weight loss?
There is no broad standard PEHP weight-loss drug benefit. But beginning July 1, 2026, eligible State of Utah members can use a narrow GLP-1 pilot inside the Weight Management Program. Other PEHP employer groups should not assume they qualify.

Does Utah Medicaid cover Wegovy for weight loss now?
The old fee-for-service pilot authorization window ended June 30, 2026, but the live Utah DHHS directory now lists a newer GLP-1 form for weight-related comorbidities. Your FFS or managed-care status and exact indication decide the current route.

Does FEP Blue cover Wegovy?
FEP Blue's current 2026 drug tool says Wegovy needs prior approval. OPM requires FEHB carriers to include at least one GLP-1 anti-obesity option, but the exact covered drug, tier, and criteria still depend on the plan option.

Is coverage for the Wegovy pen the same as the pill or HD?
Do not assume so. Regence lists separate quantities, Ro's free checker only checks the Wegovy pen, and Novo's own checker says no insurance coverage is currently available for Wegovy HD 7.2 mg.

Can a teen use Wegovy HD because Regence lists “Wegovy/Wegovy HD”?
The insurer uses that combined wording, but FDA labeling does not establish the 7.2 mg HD dose in pediatric patients. Wegovy tablets are also adult-only. The prescriber must follow the current FDA label and patient-specific medical judgment.

Will I need another approval next year?
Likely. Regence reviews at least annually and checks the benefit contract again. Ask for the approval end date and renewal criteria as soon as the first request is approved.

Does the savings card mean my plan covers Wegovy?
No. It lowers an eligible covered patient's cost under separate terms. It does not change the drug list, exclusion, or PA result. People in accumulator or maximizer programs are not eligible under Novo's current terms.

Still not sure which GLP-1 route is right for you?

Start with the one question that controls everything:

Does your exact plan include the benefit for the exact product and indication on your prescription?

Use the free router above. Then take the next step that matches the answer:

• Benefit exists → build the clean PA.
• Medical criteria were missed → fix the record or appeal.
• Product is nonformulary → use the drug-list exception route.
• Contract excludes the weight route → check only medically accurate alternate indications, then compare verified cash prices.
• Medicare → check Part D indication coverage and the Bridge.
• PEHP → check State of Utah pilot eligibility.
• FEP Blue → use the federal pharmacy route.

→ Find my Utah Wegovy route